Variations in Activin Receptor, Inhibin/activin Subunit and Follistatin MRNAs in Human Prostate Tumour Tissues

Overview

Journal Br J Cancer

Specialty Oncology

Date 2000 Jan 19

PMID 10638976

Citations 12

Authors

R H van Schaik

C D Wierikx

M A Timmerman

M H Oomen

W M van Weerden

T H van der Kwast

G J van Steenbrugge

F H de Jong

Affiliations

Soon will be listed here.

Abstract

The possible role of activin in the regulation of malignant prostatic growth was studied using RNAase protection assays of activin receptors, inhibin/activin subunits and follistatin mRNAs in the human prostatic carcinoma cell lines LNCaP-FGC, -R and -LNO, in human prostatic carcinoma xenografts and in human prostatic tissue. Activin receptor types IA (ActRIA), IB (ActRIB), IIA (ActRIIA) and IIB (ActRIIB) mRNAs were generally expressed in prostate epithelial cells, with significantly lower levels of ActRIB mRNA in prostate tumour material when compared to non-malignant tissue (P < 0.05; Mann-Whitney U-test). Inhibin/activin betaA- and betaB-subunit mRNA expression was also found in prostate tissue. Androgen-independent xenografts expressed significantly lower amounts of betaB-subunit mRNA when compared to androgen-dependent xenografts (P< 0.05). While betaB-subunit mRNA was expressed by LNCaP-FGC and -LNO cells, virtually no expression was found in the androgen-independent LNCaP-R line. Inhibin alpha-subunit mRNA levels were low or undetectable in all samples investigated. Follistatin mRNA was undetectable in LNCaP-sublines, while low levels were found in prostatic tissues. In androgen-independent LNCaP-R cells, activin inhibited cell growth in a dose-dependent manner. These results suggest that prostate tumour progression is accompanied by a decrease of the inhibitory effect of locally produced activin by either a decrease in the expression of activin betaB-subunit mRNA or by a decrease of ActRIB mRNA levels.

Citing Articles

Inhibin subunit beta B (INHBB): an emerging role in tumor progression.

Liu Y, Zhou Q, Zou G, Zhang W J Physiol Biochem. 2024; 80(4):775-793.

PMID: 39183219 DOI: 10.1007/s13105-024-01041-y.

Potential Roles of Activin in Head and Neck Squamous Cell Carcinoma Progression and Mortality.

Buryska S, Patel K, Wuertz B, Gaffney P, Ondrey F Anticancer Res. 2023; 43(12):5299-5310.

PMID: 38030164 PMC: 11285815. DOI: 10.21873/anticanres.16733.

Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy.

Cole A, Panesso-Gomez S, Shah J, Ebai T, Jiang Q, Gumusoglu-Acar E Clin Cancer Res. 2023; 29(10):1969-1983.

PMID: 36795892 PMC: 10192102. DOI: 10.1158/1078-0432.CCR-22-2254.

Integrative characterisation of secreted factors involved in intercellular communication between prostate epithelial or cancer cells and fibroblasts.

Wu Y, Clark K, Niranjan B, Chueh A, Horvath L, Taylor R Mol Oncol. 2023; 17(3):469-486.

PMID: 36608258 PMC: 9980303. DOI: 10.1002/1878-0261.13376.

Clinical and Therapeutic Implications of Follistatin in Solid Tumours.

Shi L, Resaul J, Owen S, Ye L, Jiang W Cancer Genomics Proteomics. 2016; 13(6):425-435.

PMID: 27807065 PMC: 5219916. DOI: 10.21873/cgp.20005.

References

Hoehn W, Schroeder F, Reimann J, Joebsis A, Hermanek P . Human prostatic adenocarcinoma: some characteristics of a serially transplantable line in nude mice (PC 82). Prostate. 1980; 1(1):95-104. DOI: 10.1002/pros.2990010113. View

Mellor S, Richards M, Pedersen J, Robertson D, Risbridger G . Loss of the expression and localization of inhibin alpha-subunit in high grade prostate cancer. J Clin Endocrinol Metab. 1998; 83(3):969-75. DOI: 10.1210/jcem.83.3.4640. View

Hasenson M, Kihlfors C, Lundin A, Gustafsson J, Pousette A . Effect of hormones on growth and ATP content of a human prostatic carcinoma cell line, LNCaP-r. Prostate. 1985; 7(2):183-94. DOI: 10.1002/pros.2990070208. View

Mason A, Niall H, Seeburg P . Structure of two human ovarian inhibins. Biochem Biophys Res Commun. 1986; 135(3):957-64. DOI: 10.1016/0006-291x(86)91021-1. View

Erba H, Gunning P, Kedes L . Nucleotide sequence of the human gamma cytoskeletal actin mRNA: anomalous evolution of vertebrate non-muscle actin genes. Nucleic Acids Res. 1986; 14(13):5275-94. PMC: 311540. DOI: 10.1093/nar/14.13.5275. View

Mayo K, Cerelli G, Spiess J, Rivier J, Rosenfeld M, Evans R . Inhibin A-subunit cDNAs from porcine ovary and human placenta. Proc Natl Acad Sci U S A. 1986; 83(16):5849-53. PMC: 386393. DOI: 10.1073/pnas.83.16.5849. View

Romijn J, Verkoelen C, Schroeder F . Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate. 1988; 12(1):99-110. DOI: 10.1002/pros.2990120112. View

Hedger M, Drummond A, Robertson D, Risbridger G, de Kretser D . Inhibin and activin regulate [3H]thymidine uptake by rat thymocytes and 3T3 cells in vitro. Mol Cell Endocrinol. 1989; 61(1):133-8. DOI: 10.1016/0303-7207(89)90198-6. View

Gonzalez-Manchon C, Vale W . Activin-A, inhibin and transforming growth factor-beta modulate growth of two gonadal cell lines. Endocrinology. 1989; 125(3):1666-72. DOI: 10.1210/endo-125-3-1666. View

10.

Hashimoto M, Kondo S, Sakurai T, Etoh Y, Shibai H, Muramatsu M . Activin/EDF as an inhibitor of neural differentiation. Biochem Biophys Res Commun. 1990; 173(1):193-200. DOI: 10.1016/s0006-291x(05)81040-x. View

11.

RUBIN S, Hallahan D, ASHMAN C, Brachman D, Beckett M, Virudachalam S . Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol. 1991; 46(1):31-6. DOI: 10.1002/jso.2930460108. View

12.

van Steenbrugge G, van Uffelen C, Bolt J, Schroder F . The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity. J Steroid Biochem Mol Biol. 1991; 40(1-3):207-14. DOI: 10.1016/0960-0760(91)90184-7. View

13.

Donaldson C, Mathews L, Vale W . Molecular cloning and binding properties of the human type II activin receptor. Biochem Biophys Res Commun. 1992; 184(1):310-6. DOI: 10.1016/0006-291x(92)91194-u. View

14.

Feng Z, Madigan M, Chen C . Expression of type II activin receptor genes in the male and female reproductive tissues of the rat. Endocrinology. 1993; 132(6):2593-600. DOI: 10.1210/endo.132.6.7916681. View

15.

Hilden K, Tuuri T, Eramaa M, Ritvos O . Expression of type II activin receptor genes during differentiation of human K562 cells and cDNA cloning of the human type IIB activin receptor. Blood. 1994; 83(8):2163-70. View

16.

Carcamo J, Weis F, Ventura F, Wieser R, Wrana J, Attisano L . Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin. Mol Cell Biol. 1994; 14(6):3810-21. PMC: 358748. DOI: 10.1128/mcb.14.6.3810-3821.1994. View

17.

Ten Dijke P, Franzen P, Yamashita H, Ichijo H, Heldin C, Miyazono K . Serine/threonine kinase receptors. Prog Growth Factor Res. 1994; 5(1):55-72. DOI: 10.1016/0955-2235(94)90017-5. View

18.

Mathews L . Activin receptors and cellular signaling by the receptor serine kinase family. Endocr Rev. 1994; 15(3):310-25. DOI: 10.1210/edrv-15-3-310. View

19.

Risbridger G, Thomas T, Gurusinghe C, McFarlane J . Inhibin-related proteins in rat prostate. J Endocrinol. 1996; 149(1):93-9. DOI: 10.1677/joe.0.1490093. View

20.

Massague J . TGFbeta signaling: receptors, transducers, and Mad proteins. Cell. 1996; 85(7):947-50. DOI: 10.1016/s0092-8674(00)81296-9. View